-- 週四,受美伊停火談判破裂的擔憂影響,德國藍籌股DAX指數逆轉早盤漲幅,收跌1.14%。 由於以色列在黎巴嫩持續的軍事行動令地區穩定緊張,霍爾木茲海峽的航運仍然癱瘓。對此,德黑蘭威脅要放棄與華盛頓剛達成的停火協議,而美國總統川普則警告稱,如果無法達成全面協議,將再次升級軍事衝突。 在國內,德國聯邦統計局(Destatis)公佈的數據顯示,2月份德國工業生產季減0.3%,低於1月修正後的零成長,也低於市場預期的0.9%。年比來看,工業產出維持穩定,先前修正後的年減幅為0.9%。 「今天早上公佈的宏觀經濟數據是描繪中東戰爭爆發前德國經濟狀況的最後一批數據。數據顯示,消費者非常猶豫不決,而製造業則難以獲得積極的增長勢頭。目前唯一能讓我們繼續沿用『番茄醬瓶』比喻的證據是昨天公佈的工業訂單數據,該數據證實國防工業的訂單仍在繼續增長。這至少在一定程度上支持了我們長期以來的工業訂單數據,該數據證實國防工業的訂單仍在繼續增長。這至少在一定程度上支持了我們長期以來的經濟觀點。 同時,德國2月經曆法和季節性調整後的貿易順差為198億歐元,低於上月修正後的203億歐元和預期的181億歐元。根據聯邦統計局的數據,出口較上季成長3.6%,高於先前修正後的1.5%的降幅和預期的1%的成長。月進口量成長4.7%,高於先前修正後的5.1%的降幅,也高於市場預期的4%增幅。 公司新聞方面,賓士集團(MBG.F)股價下跌2.02%,此前該公司公佈第一季交付量為499,700輛,較去年同期下降6%。這家德國汽車製造商表示,業績符合公司預期。 加拿大皇家銀行資本市場將漢高(HEN.F)的調整後每股收益預期和目標股價從75歐元下調至73歐元,因為擔心執行風險可能會限制近期品牌收購帶來的營收成長。 加拿大皇家銀行(RBC)寫道:「收購Not Your Mother's和OLAPLEX將填補漢高現有護髮產品組合的空白,並使該公司成為消費者護髮領域更具競爭力的品牌。 如果執行得當,整合這些品牌有望在中期內為其護髮業務帶來50個基點的收入增長。
Related Articles
Research Alert: CFRA Keeps Buy Opinion On Shares Of The Hartford Insurance Group, Inc.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We trim our 12-month target price by $8 to $155, valuing HIG shares at 11.3x our 2026 operating EPS estimate of $13.75 (cut by $0.45) and at 10.6x our 2027 EPS estimate of $14.65 (cut by $0.30), vs. the shares' one-year average forward multiple of 10.3x and peer average of 13x. Q1 EPS of $3.09 vs. $2.20 a year ago missed our $3.60 estimate and $3.39 consensus view. Operating revenue growth of 6.2% was in line with our 6%-10% forecast, amid 5.3% earned premium growth, 13% higher net investment income, and 7.9% fee revenue growth. Q1 written premium growth of 4% and full-year 2025 growth of 7% bode well for 2026 revenue trends as premiums are earned. Underwriting results improved significantly, with Personal Lines combined ratio improving to 87.7% from 106.1% and underlying combined ratio to 85.0% from 89.7%. Business Insurance combined ratio was stable at 94.8%. Weighing the Q1 EPS miss with HIG's decent top-line growth and discounted valuation to peers, we view the shares as undervalued.
Research Alert: CFRA Keeps Strong Buy Opinion On Shares Of Baker Hughes
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We raise our 12-month target price by $14 to $82, reflecting a combination of our sum-of-the-parts (SOTP) and DCF models. For our SOTP model, we presume the oilfield services business (about 50% of BKR's franchise) to be valued at about 10x projected 2027 EBITDA (in line with major peers) and its industrial energy technology business (the other 50%) valued at 14x projected 2027 EBITDA (in line with the peer median). This blended approach, yielding a 12x multiple, implies a value of $73 per share. Meanwhile, our DCF model, using medium-term free cash flow growth of 5% per year, terminal growth of 2.5%, discounted at a WACC of 6.3%, yields intrinsic value of $91 per share. We cut our 2026 EPS estimate by $0.47 to $2.48, but we raise 2027's by $0.07 to $3.24. We acknowledge that the oilfield services business is likely to struggle in 2026 owing to the U.S.-Iran conflict, but the IET business appears quite robust and likely to be a source of both accelerating revenue growth and margins.
Research Alert: CFRA Maintains Hold Opinion In Shares Of Wab
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lift our 12-month target to $285 from $275 following WAB's Q1 earnings print, valuing shares at 24.2x our 2027 EPS outlook of $11.76 (revised from $11.46; 2026 EPS estimate up to $10.57 from $10.50), a slight premium to WAB's long-term historical multiple average given structural improvements in earnings quality. While we are cautious on signs of overcapacity in the freight market, an elevated order backlog (12-month sits at over $9 billion), internal initiatives to shore up margins, and potential synergies from M&A activity positions WAB to continue growing earnings at double-digit rates in 2026-2027, in our view. Despite tariff-related cost pressures, WAB has done a commendable job of defending margins via a mix of pricing, lean manufacturing, and pruning of lower-profit operations. Q1 results were mixed but overall positive, in our view. We maintain our Hold recommendation on shares.